Peptide Database
86 therapeutic peptides with research summaries, clinical findings, and regulatory status.
Bivalirudin (Angiomax)
A synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor by binding both the catalytic active site and anion-binding exosite 1 of thrombin. Bivalirudin inhibits both free and clot-bound thrombin, providing more predictable anticoagulation than heparin without requiring antithrombin III as a cofactor. It is enzymatically cleaved by thrombin itself, producing a self-limiting anticoagulant effect with a 25-minute half-life.
Romiplostim (Nplate)
A thrombopoietin (TPO) receptor agonist consisting of a peptide sequence that binds the TPO receptor (c-Mpl) fused to an IgG1 Fc domain (peptibody). Romiplostim activates JAK2/STAT5 signaling in megakaryocyte progenitors, promoting megakaryocyte proliferation, differentiation, and platelet production. It has no sequence homology to endogenous TPO, minimizing the risk of cross-reactive antibody formation.
Pegcetacoplan (Empaveli)
A pegylated cyclic peptide that inhibits complement component C3, the central node of all three complement activation pathways (classical, lectin, and alternative). By binding C3 and preventing its cleavage into C3a and C3b, pegcetacoplan blocks both intravascular hemolysis (mediated by membrane attack complex) and extravascular hemolysis (mediated by C3b opsonization and phagocytosis). This dual mechanism addresses the limitation of C5 inhibitors that only prevent intravascular hemolysis.